Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 13/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 2/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3723610 | 1.00 | HDAC4 (0.42) | HDAC4HDAC6IKBKBCHEK1ACHE | |
| SCHEMBL473788 | 0.98 | IKBKB (0.43) | HDAC4HDAC6IKBKBCHEK1ACHE | |
| SCHEMBL3723523 | 0.98 | IKBKB (0.43) | HDAC4HDAC6IKBKBCHEK1ACHE | |
| SCHEMBL3725168 | 0.88 | SUV39H2 (0.46) | HDAC4HDAC6IKBKBCHEK1ACHE | |
| SCHEMBL473718 | 0.86 | SYK (0.41) | CHEK1ACHEMETCHEK2SUV39H2 | |
| SCHEMBL473787 | 0.86 | SYK (0.41) | CHEK1ACHEMETCHEK2SUV39H2 | |
| SCHEMBL11909311 | 0.86 | PIM1 (0.41) | IKBKBCHEK1ACHEMETCHEK2 | |
| SCHEMBL11908069 | 0.86 | PIM1 (0.41) | IKBKBCHEK1ACHEMETCHEK2 | |
| SCHEMBL473674 | 0.85 | IKBKB (0.40) | HDAC4HDAC6IKBKBCHEK1ACHE | |
| SCHEMBL473640 | 0.84 | CHEK1 (0.43) | CHEK1ACHEMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| WO-2010109084-A2 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NPR3, CCNH, CBR3 | HDAC4 1980/4885HDAC6 1375/4885IKBKB 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.